NCT06995105 is a Phase 1, PHASE2 clinical trial of TACE in Advanced Hepatocellular Carcinoma (HCC), sponsored by Zhejiang University.

Who is sponsoring NCT06995105?

NCT06995105 is sponsored by Zhejiang University.

What drugs are being tested in NCT06995105?

Interventions in NCT06995105: TACE, Sintilimab combined with Bevacizumab, individualized anti-tumor new antigen iNeo-Vac-R01 injection.

What condition does NCT06995105 study?

NCT06995105 studies Advanced Hepatocellular Carcinoma (HCC).

Is NCT06995105 still recruiting?

NCT06995105 is currently recruiting now. Last updated 29 May 2025.

Last reviewed 2025-05-29 · How we verify

NCT06995105

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma

Recruiting now Phase 1, PHASE2 Last updated 29 May 2025

What this trial tests

Phase 1, PHASE2 trial testing TACE in Advanced Hepatocellular Carcinoma (HCC) in 30 participants. Currently enrolling.

Timeline

9 April 2025

Primary endpoint
1 April 2027

1 April 2028

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	9 April 2025
Primary completion	1 April 2027
Estimated completion	1 April 2028
Sites	1 location across China

Drugs / interventions tested

TACE
Sintilimab combined with Bevacizumab — full drug profile →
individualized anti-tumor new antigen iNeo-Vac-R01 injection — full drug profile →

Conditions studied

Advanced Hepatocellular Carcinoma (HCC) — all drugs for Advanced Hepatocellular Carcinoma (HCC) →

Sponsor

Zhejiang University

Who can join

Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody and TACE regimen for the treatment of patients with advanced hepatocellular carcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.
Sun S, Liu L, Zhang J, Sun L, et al · · 2025 · cited 17× · PMID 40898324 · DOI 10.1186/s13045-025-01732-z

Verify or expand the search:

Other trials of TACE

Trials testing the same drug.

NCT07487662 — TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcin · Phase 2 · not yet recruiting
NCT07417800 — Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinom · NA · not yet recruiting
NCT07398664 — H101 Plus TACE for r/m HNSCC · Phase 2 · not yet recruiting
NCT07340502 — TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma · not yet recruiting
NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Advanced Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
NCT07500220 — Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC · Phase 1, PHASE2 · recruiting
NCT07123545 — Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT06902389 — A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07039201 — A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) · NA · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06995105 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 29 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06995105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing